Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
The clinical protocols align with the Endocrine Society's 2024 Obesity Pharmacotherapy Guideline and the AACE Comprehensive Type 2 Diabetes Management Algorithm 2024, per the brand's published medical review policy
Leyden J, Dunleavy K
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
This can result in more muscle mass, improved fat metabolism, enhanced skin quality, and potentially anti-aging effects
From this perspective, neuroprotection must be reframed as a systemic, integrated endeavor
